Innate Pharma S.A.

ENXTPA:IPH 주식 리포트

시가총액: €112.6m

Innate Pharma 경영진

경영진 기준 점검 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Jonathan Dickinson

최고경영자

€939.6k

총 보수

CEO 급여 비율58.53%
CEO 재임 기간1.5yrs
CEO 지분 보유율n/a
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간1yr

최근 경영진 업데이트

Recent updates

IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story

Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.

IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside

Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.

Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates

Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates

IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple

Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.

IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple

Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.

IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple

Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.

IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside

Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.

IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential

Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).

IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside

Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities

Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.

Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing

Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
User avatar

Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities

A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.

News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%

Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%

Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%

Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%

Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

CEO 보수 분석

Jonathan Dickinson의 보수는 Innate Pharma의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025€940k€550k

-€49m

Sep 30 2025n/an/a

-€48m

Jun 30 2025n/an/a

-€46m

Mar 31 2025n/an/a

-€48m

Dec 31 2024€435k€92k

-€49m

보상 대 시장: Jonathan의 총 보수(USD1.10M)는 French 시장에서 비슷한 규모 기업의 평균(USD337.28K)보다 높습니다.

보상과 수익: Jonathan의 보상은 회사가 적자임에도 증가했습니다.

CEO

Jonathan Dickinson (57 yo)

1.5yrs
재임 기간
€939,625
보수

Mr. Jonathan E. Dickinson, MBA, BSc served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. Mr. Dickinson is Chief Executive Officer of Innate P...

리더십 팀

이름직위재임 기간보수지분
Jonathan Dickinson
CEO & Director1.5yrs€939.63k데이터 없음
Yannis Morel
Executive VP & COO2.3yrs€163.69k0.40%
€ 449.0k
Sonia Quaratino
Executive VP & Chief Medical Officer1.3yrs€188.14k데이터 없음
François Romagné
Founderno data데이터 없음데이터 없음
Marc Bonneville
Founderno data데이터 없음데이터 없음
Jean Fournié
Founderno data데이터 없음데이터 없음
Alessandro Moretta
Founderno data데이터 없음데이터 없음
Frederic Lombard
Senior VP & CFO5.1yrs데이터 없음0.080%
€ 90.2k
Stephanie Cornen
Vice President of Investor Relations1.3yrs데이터 없음0.032%
€ 35.5k
Odile Belzunce
VP, Chief of Compliance & Operations Officer and Interim Head of HR7.3yrs데이터 없음0.15%
€ 163.5k
Claire de Blanquat
VP of Legal & Corporate Affairs and Secretary of the Supervisory Board3.3yrs데이터 없음0.054%
€ 60.8k
2.3yrs
평균 재임 기간
52yo
평균 나이

경험이 풍부한 관리: IPH의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.3 년).

이사회 구성원

이름직위재임 기간보수지분
Jonathan Dickinson
CEO & Director1yr€939.63k데이터 없음
Olivier Martinez
Director1yr데이터 없음데이터 없음
Christian Itin
Director1yr€34.00k데이터 없음
Martin Duvall
Director1yr€41.50k데이터 없음
Sally Bennett
Independent Director1yr€85.00k0.0027%
€ 3.0k
Irina Staatz-Granzer
Independent Chairwoman of the Board1yr데이터 없음0.027%
€ 30.1k
Pascale Boissel
Independent Vice Chairperson of the Board1yr€89.50k0.0011%
€ 1.2k
Veronique Chabernaud
Independent Director1yr€79.00k0.00070%
€ 788.2
Katy Rezvani
Strategic Advisory Board Member2.3yrs데이터 없음데이터 없음
Aurelien Marabelle
Strategic Advisory Board Member7.5yrs데이터 없음데이터 없음
1.0yrs
평균 재임 기간
60yo
평균 나이

경험이 풍부한 이사회: IPH의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 1 년) — 신규 이사회일 가능성이 있습니다.

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/04 17:21
종가2026/05/04 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Innate Pharma S.A.는 13명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Justin ZelinBTIG
Suranjit MukherjeeBTIG
Yigal NochomovitzCitigroup Inc